La vendita allo scoperto per KKR dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di KKR. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

KKR (NYSE:KKR) Azioni, Report sulle vendite allo scoperto

KKR & Co

KKR is one of the world's largest alternative asset managers, with $624.4 billion in total managed assets, including $505.7 billion in fee-earning AUM, at the end of September 2024. The company has two core segments: asset management (which includes private markets-private equity, credit, infrastructure, energy, and real estate-and public markets-primarily credit and hedge/investment fund platforms) and insurance (following the firm's initial investment in, and then ultimate purchase of, Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance).

Wall Street Braces for More Uncertainty

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

PAYO

PIPR

Payoneer, KKR e Piper Sandler: l&#39;RSI segnala eccesso di vendite, ma è davvero il momento di puntare su questi titoli del settore finanziario?

3 azioni finanziarie che potrebbero salire dopo il recente sell-off

Settore utility sotto pressione: segnali d&#39;allarme in aumento per alcuni titoli chiave. Analisti finanziari lanciano l&#39;allerta su 3 titoli.

Utility a rischio? 3 titoli ipercomprati da vendere prima che sia troppo tardi

KKR & Co Inc

KATAKURA INDSTRS CO LTD by Katakura Industries Co Ltd

Katakura Industries Co Ltd

KKR Group Finance Co. IX LLC 4.625% Subordinated Notes due 2061

KKR & Co. Inc. 6.25% Series D Mandatory Convertible Preferred Stock

KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) shares are trading higher on Monday. S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) and CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) inked a deal to sell OSTTRA to investment funds managed by KKR at a <a href="https://www.benzinga.com/pressreleases/25/04/n44785236/s-p-global-and-cme-group-to-sell-osttra-to-kkr-for-3-1-billion" target="_blank" rel="noreferrer noopener">total enterprise value of $3.1 billion</a>.
Formed in 2021 through a joint venture between CME and S&amp;P Global, OSTTRA delivers essential post-trade services to the global financial industry.
OSTTRA supports the full trade lifecycle—enabling seamless connectivity and efficient workflows for banks, broker-dealers, asset managers, and other market participants across trade processing and optimization.
As equal partners in the joint venture, S&amp;P Global and CME Group will split the proceeds from the sale equally.
Notably, KKR is acquiring OSTTRA primarily through its North American private equity platform.
Upon completion of the transaction, KKR intends to implement a broad-based equity ownership plan, allowing nearly all of OSTTRA's approximately 1,500 employees to share in the company's future growth.
The deal is expected to close in the second half of 2025, pending regulatory approvals and other customary closing conditions.
Guy Rowcliffe and John Stewart, co-CEOs of OSTTRA said, &#8220;With KKR&#8217;s support, we will further accelerate our strategic initiatives to enhance our market-leading post-trade solutions, drive innovation, and expand our global footprint.&#8221;
Last week, KKR secured a deal to acquire Swedish consumer health firm&nbsp;Karo Healthcare, which is expected to be valued at around 2.65 billion <a target="_blank" href="https://www.benzinga.com/markets/equities/25/04/44725000/kkr-outbids-competitors-to-secure-2-9-billion-karo-healthcare-takeover" rel="noreferrer noopener">euros ($2.924 billion), including debt</a>.
KKR plans to release first-quarter <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">FY25 results on May 1, 2025</a>.
Investors can gain exposure to KKR via FM Focus Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMCX#NYSE">FMCX</a>) and EA Series Trust WHITEWOLF Publicly Listed Private Equity ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/LBO#BATS">LBO</a>).
Price Action: KKR shares are up 1.25% at $102.71 at last check Monday.
Read Next:&nbsp;&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44634677/goldman-sachs-sees-broad-eps-pressure-across-capital-markets-highlights-brookfield-as-a-standout" target="_blank" rel="noreferrer noopener">Goldman Sachs Sees Broad EPS Pressure Across Capital Markets, Highlights Brookfield As A Standout</a></li>
</ul>
Photo: Shutterstock

Equities

Large Cap

Movers

Northern Lights Fund Trust IV FMC Excelsior Focus Equity ETF

FMCX

SPGI

KKR Targets Backbone Of Global Trading With $3.1 Billion OSTTRA Acquisition

Morgan Stanley analyst Michael Cyprys maintains KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) with a Equal-Weight and lowers the price target from $156 to $114.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on KKR, Lowers Price Target to $114

WIIM

KKR shares are trading higher after the company announced it will buy OSTRA for $3.1 billion.

S&amp;P Global and CME Group today announced the signing of a definitive agreement to sell OSTTRA, a leading provider of post-trade solutions for the global OTC market, to investment funds managed by KKR, a leading global investment firm.&nbsp; The terms of the deal for OSTTRA equaled total enterprise value at $3.1 billion, subject to customary purchase price adjustments, which will be divided evenly between S&amp;P Global and CME Group pursuant to their 50/50 joint venture.
&nbsp;
Established in 2021 as a joint venture between CME Group and S&amp;P Global, OSTTRA serves the global financial ecosystem with a comprehensive suite of critical post-trade offerings across interest rates, FX, credit and equity asset classes. OSTTRA provides end-to-end connectivity and workflow solutions to banks, broker-dealers, asset managers, and other market participants across trade processing, trade lifecycle, and optimization.
The OSTTRA management team, led by co-CEOs&nbsp;Guy Rowcliffe and John Stewart, will continue to lead the company in their current roles. KKR will support OSTTRA's customer-centric growth and role as a critical market infrastructure provider by increasing OSTTRA's investments in technology and innovation across its leading post-trade solutions platform.

Asset Sales

S&P Global and CME Group Sell OSTTRA to KKR for $3.1B, Focused on Post-Trade Solutions Growth

Barclays analyst Benjamin Budish maintains KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) with a Overweight and lowers the price target from $181 to $129.

Barclays Maintains Overweight on KKR, Lowers Price Target to $129

ALLY

ARCC

ARES

CADE

EWBC

FITB

HBAN

HOMB

HSBC

IBKR

NDAQ

NTRS

RITM

SCHW

SOFI

TROW

VOYA

ZION

Shares of banks and financial services companies are trading lower as stocks pull back after surging Wednesday following President Trump's tariff pause announcement.

KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) has secured a deal to acquire Swedish consumer health firm Karo Healthcare<a target="_blank" href="https://www.benzinga.com/25/02/43907861/kkr-to-gain-full-control-of-hcg-in-400-million-deal-eyes-healthcare-expansion" rel="noreferrer noopener">.</a>
The transaction is subject to customary regulatory conditions and approvals and is expected to close in the coming months, per a <a target="_blank" href="https://eqtgroup.com/news/eqt-to-sell-karo-healthcare-a-leading-pan-european-consumer-health-platform-to-kkr-2025-04-09" rel="noreferrer noopener">statement</a>.&nbsp;
"We engaged the full capabilities of our firm to deliver this transaction during a period of market disruption and we look forward to supporting Karo's growth as a value-enhancing strategic partner," said Hans Arstad, Managing Director at KKR.
The transaction, expected to be valued at approximately 2.65 billion euros ($2.924 billion) including debt, would see KKR beat out rival bidder PAI Partners to secure the company behind popular over-the-counter brands like E45 and Lamisil, Financial Times <a target="_blank" href="https://www.ft.com/content/59680d34-adb9-473a-8c95-9f89ac9e1555" rel="noreferrer noopener">reports</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44514266/kkr-mulls-to-buy-japan-based-eye-care-company-topcon" rel="noreferrer noopener">KKR Mulls To Buy Japan-Based Eye Care Company Topcon</a>
Karo Healthcare, headquartered in Stockholm, has expanded significantly under the ownership of EQT, which took the firm private in 2022 at a valuation of 1.4 billion euros.
EQT initially took a majority stake in Karo back in 2019 when the business was still listed, Financial Times adds.
The acquisition underscores KKR's confidence in healthcare-focused investments even as overall merger activity has slowed due to uncertain interest rate policy and fluctuating debt markets.
The buyout is poised to provide a strong return for EQT, following a series of brand acquisitions Karo made in recent years.
Under EQT's stewardship, Karo spent £200 million in 2021 to acquire the E45 skincare line from Reckitt Benckiser Group Plc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RBGLY#OTC">RBGLY</a>), and in 2023 it purchased Lamisil from Haleon Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>) for £235 million. The company currently markets over 100 products across 90 countries, with a portfolio that includes Nutravita, Alpha Foods, and Remescar. Karo employs about 400 people globally.
This deal would further KKR's extensive footprint in the European healthcare sector.
The firm, which manages $668 billion in assets, has recently invested in U.K.-based Clinisupplies and Swiss peptide manufacturer Biosynth, among others.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, KKR stock has lost over 5% in the past year. Investors can gain exposure to the stock via FM Focus Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMCX#NYSE">FMCX</a>).
Price Action: KKR shares closed higher by 16.90% to $110.46&nbsp;on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44706944/elon-musk-warns-those-who-financed-tesla-attacks-will-go-to-prison" target="_blank" rel="noreferrer noopener">Elon Musk Warns Those Who Financed Tesla Attacks ‘Will Go To Prison'</a></li>
</ul>
Photo via Shutterstock

Media

General

RBGLY

KKR Outbids Competitors To Secure $2.9 Billion Karo Healthcare Takeover

KKR shares are trading higher. TD Cowen maintained a Buy rating on the stock.

TD Cowen analyst Bill Katz maintains KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) with a Buy and lowers the price target from $183 to $126.

TD Cowen Maintains Buy on KKR, Lowers Price Target to $126

Wells Fargo analyst Michael Brown maintains KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) with a Overweight and lowers the price target from $141 to $120.

Wells Fargo Maintains Overweight on KKR, Lowers Price Target to $120

Citigroup analyst Chris Allen maintains KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) with a Buy and lowers the price target from $177 to $132.

Citigroup Maintains Buy on KKR, Lowers Price Target to $132

<a href="https://www.bloomberg.com/news/articles/2025-04-08/kkr-nears-deal-to-buy-karo-for-more-than-2-5-billion" title="https://www.bloomberg.com/news/articles/2025-04-08/kkr-nears-deal-to-buy-karo-for-more-than-2-5-billion">https://www.bloomberg.com/news/articles/2025-04-08/kkr-nears-deal-to-buy-karo-for-more-than-2-5-billion</a>

'KKR Nears Deal To Buy Karo Healthcare For More Than €2.5 Billion' - Bloomberg News

Investors with a lot of money to spend have taken a bearish stance on KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with KKR, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 21 uncommon options trades for KKR.
This isn't normal.
The overall sentiment of these big-money traders is split between 28% bullish and 71%, bearish.
Out of all of the special options we uncovered, 16 are puts, for a total amount of $1,221,906, and 5 are calls, for a total amount of $315,882.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $100.0 to $125.0 for KKR over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in KKR's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to KKR's substantial trades, within a strike price spectrum from $100.0 to $125.0 over the preceding 30 days.
<h3>KKR 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744139409_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>KKR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$13.6</td>
<td>$13.5</td>
<td>$13.6</td>
<td>$100.00</td>
<td>$312.8K</td>
<td align="right">160</td>
<td align="right">151</td>
</tr>
<tr>
<td>KKR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$13.6</td>
<td>$13.4</td>
<td>$13.6</td>
<td>$100.00</td>
<td>$179.5K</td>
<td align="right">160</td>
<td align="right">702</td>
</tr>
<tr>
<td>KKR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$7.2</td>
<td>$6.4</td>
<td>$7.2</td>
<td>$120.00</td>
<td>$136.8K</td>
<td align="right">431</td>
<td align="right">190</td>
</tr>
<tr>
<td>KKR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$13.6</td>
<td>$13.5</td>
<td>$13.6</td>
<td>$100.00</td>
<td>$95.2K</td>
<td align="right">160</td>
<td align="right">492</td>
</tr>
<tr>
<td>KKR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$13.6</td>
<td>$13.5</td>
<td>$13.6</td>
<td>$100.00</td>
<td>$87.0K</td>
<td align="right">160</td>
<td align="right">284</td>
</tr>
</tbody>
</table>

<h3>About KKR</h3>
KKR is one of the world's largest alternative asset managers, with $624.4 billion in total managed assets, including $505.7 billion in fee-earning AUM, at the end of September 2024. The company has two core segments: asset management (which includes private markets-private equity, credit, infrastructure, energy, and real estate-and public markets-primarily credit and hedge/investment fund platforms) and insurance (following the firm's initial investment in, and then ultimate purchase of, Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance).
Having examined the options trading patterns of KKR, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of KKR</h3>
<ul>
<li>With a volume of 8,140,315, the price of KKR is up 5.42% at $102.83. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 22 days.</li>
</ul>
<h3>What Analysts Are Saying About KKR</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $161.67.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has elevated its stance to Overweight, setting a new price target at $141. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on KKR, which currently sits at a price target of $194. 
&#x2A; Consistent in their evaluation, an analyst from JMP Securities keeps a Market Outperform rating on KKR with a target price of $150. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest KKR options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Decoding KKR's Options Activity: What's the Big Picture?

JMP Securities analyst Devin Ryan maintains KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) with a Market Outperform and lowers the price target from $165 to $150.

JMP Securities Maintains Market Outperform on KKR, Lowers Price Target to $150

Shares of some banking and financial services stocks are trading higher as markets rebound following earlier weakness.

Analysts' ratings for KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for KKR, presenting an average target of $164.25, a high estimate of $194.00, and a low estimate of $141.00. Highlighting a 2.16% decrease, the current average has fallen from the previous average price target of $167.88. 
<img src="https://www.benzinga.com/files/images/story/2025/1743796873_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of KKR's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$194.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$141.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$156.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$181.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Vikram Gandhi</td>
<td>HSBC</td>
<td>Raises</td>
<td>Hold</td>
<td>$173.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$151.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$168.00</td>
<td>$170.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to KKR. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of KKR compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for KKR's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into KKR's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KKR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on KKR analyst ratings.</a>
<h2>Get to Know KKR Better</h2>
KKR is one of the world's largest alternative asset managers, with $624.4 billion in total managed assets, including $505.7 billion in fee-earning AUM, at the end of September 2024. The company has two core segments: asset management (which includes private markets-private equity, credit, infrastructure, energy, and real estate-and public markets-primarily credit and hedge/investment fund platforms) and insurance (following the firm's initial investment in, and then ultimate purchase of, Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance).
<h3>A Deep Dive into KKR's Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Decline in Revenue: Over the 3 months period, KKR faced challenges, resulting in a decline of approximately -26.81% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: KKR's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 35.17%, the company may face hurdles in effective cost management.
Return on Equity (ROE): KKR's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.72% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.31%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.15, caution is advised due to increased financial risk.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

8 Analysts Have This To Say About KKR

KKR shares are trading lower after B of A Securities cut its price target on the stock from $214 to $194.

B of A Securities analyst Craig Siegenthaler maintains KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) with a Buy and lowers the price target from $214 to $194.

B of A Securities Maintains Buy on KKR, Lowers Price Target to $194

Goldman Sachs analyst Alexander Blostein expects macro and policy uncertainty, volatile equity markets, and declining short-term interest rates to weigh on EPS <a target="_blank" href="https://www.benzinga.com/topic/bank" rel="noreferrer noopener">forecasts for Capital Markets stocks</a>.
The analyst&#8217;s 2025 estimates are ~5% below consensus on average, except for Exchanges.
Blostein says Alternative Manager stocks face heightened EPS risks due to weaker realization activity (potential 30% downside to Street estimates) and a slower FRE growth trajectory, now expected to average 11% in 2025E,<a target="_blank" href="https://www.benzinga.com/quote/tpg/analyst-ratings" rel="noreferrer noopener"> down from ~15% previously</a>.
The analyst writes that Brookfield Asset Management Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) appears among the most resilient, <a target="_blank" href="https://www.benzinga.com/quote/bam/analyst-ratings" rel="noreferrer noopener">benefiting from index inclusion</a>.
While TPG Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) and KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) offer attractive valuations, further EPS estimate revisions may be <a target="_blank" href="https://www.benzinga.com/quote/kkr/analyst-ratings" rel="noreferrer noopener">necessary, adds the analyst</a>.
On the other hand, the analyst says that the Brokers and Wealth Advisor stocks face an average 4%<a target="_blank" href="https://www.benzinga.com/quote/schw/analyst-ratings" rel="noreferrer noopener"> downside to 2025/2026 EPS estimates</a>.
Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) is performing better (+5% first-quarter EPS beat), while Stifel Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SF#NYSE">SF</a>) is lagging <a target="_blank" href="https://www.benzinga.com/quote/sf/analyst-ratings" rel="noreferrer noopener">(-10% EPS miss), adds the analyst</a>.
Blostein expects lower short-term interest rates, weaker equity markets, and slower Investment Banking activity in 2025 to weigh on EPS, though he anticipates higher cash balances in March and stronger retail engagement to provide some relief.
Meanwhile, the analyst projects Traditional Managers to face ~5% EPS downside in 2025/26, with T. Rowe Price Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>) and Janus Henderson Group plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>) facing high-single-digits <a target="_blank" href="https://www.benzinga.com/quote/jhg/analyst-ratings" rel="noreferrer noopener">EPS risks in 2025/26.</a>
Blostein expects long-term average AUM to decline ~1% q/q, with <a target="_blank" href="https://www.benzinga.com/quote/trow/analyst-ratings" rel="noreferrer noopener">weaker second-quarter momentum</a>.
Fixed Income and Active ETFs show strength, but Active Equities outflows may drive a -2.0% annualized organic decline, adds the analyst.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44629640/us-services-sector-slows-sharply-as-hiring-drops-tariff-pressures-mount" target="_blank" rel="noreferrer noopener">US Services Sector Slows Sharply As Hiring Drops, Tariff Pressures Mount</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Mid Cap

Janus Henderson Group plc Ordinary Shares

Goldman Sachs Sees Broad EPS Pressure Across Capital Markets, Highlights Brookfield As A Standout

KKR Drops Out Of Consortium Seeking Gerresheimer Takeover

Press Releases

KKR Announces Intra-Quarter Monetization Activity Update for the First Quarter

KKR Enters into MoU with Founding Family of FUJI SOFT; to Acquire 100% of FUJI SOFT

Topcon to Accelerate Growth through Management Buyout with KKR and JIC Capital

Global Atlantic 2025 Retirement Outlook Survey: Majority of Investors Worried about Outliving Assets

ReliaQuest Raises More Than $500 Million in Funding at a Valuation of $3.4 Billion

Sylvan Receives Investment from Novo Holdings to Drive Further Growth

KKR & Co. Inc. to Announce First Quarter 2025 Results

FSK Announces Earnings Release and Conference Call Schedule for First Quarter 2025

S&P Global and CME Group to sell OSTTRA to KKR for $3.1 billion

/C O R R E C T I O N -- S&P Global/

AllianceBernstein Holding

Affiliated Managers Group, Inc. Common Stock

Affiliated Managers Group

Ameriprise Finl

Ares Capital Corporation - Closed End Fund

Ares Capital

Ares Management Corporation Class A Common Stock

Ares Management

Franklin Resources

The Bank of New York Mellon Corporation Common Stock

Bank of New York Mellon

BlackRock

Brookfield Corporation Class A Limited Voting Shares

Brookfield

Blackstone

Blackstone Secured Lending Fund Common Shares of Beneficial Interest

Blackstone Secured

Carlyle Group

Cohen & Steers

FS KKR Capital

Hamilton Lane Incorporated - Class A Common Stock

Hamilton Lane

Invesco

Janus Henderson Group

Main Street Capital Corporation Common Stock

Main Street Capital

Northern Trust Corporation - Common Stock

Northern Trust

Blue Owl Capital Corporation Common Stock

Blue Owl Capital

Blue Owl Capital Inc. Class A Common Stock

Comments

KKR

Vendite allo scoperto

KKR (NYSE:KKR) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO